Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio
09:30am, Saturday, 30'th Aug 2025
Incyte's share price continues to soar despite Trump's repeated threats to cut drug prices. One of the key reasons behind the continued upward momentum was Incyte's strong financial results for Q2 202
Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?
07:14am, Friday, 29'th Aug 2025
During a year when healthcare stocks, especially biotechnology, have lagged so deeply behind the overall market, it's particularly noteworthy that Incyte Corporation NASDAQ: INCY has managed to stand
Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue?
12:31pm, Thursday, 28'th Aug 2025
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Wednesday, 27'th Aug 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
08:00am, Monday, 25'th Aug 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer.
INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?
11:21am, Wednesday, 20'th Aug 2025
Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.
Incyte to Present at Upcoming Investor Conferences
08:00am, Tuesday, 19'th Aug 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conferences.
Cancer Stock Soars While This China Tech Stock Heads To New Highs
02:50pm, Friday, 15'th Aug 2025
Cancer stock Incyte soared on earnings and touched a new high on Friday. Also at new highs, Lidar maker Hesai group shows ideal relative strength.
CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on d
Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis
04:05pm, Tuesday, 05'th Aug 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil
04:30pm, Thursday, 31'st Jul 2025
MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, Unit
Why Incyte (INCY) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 30'th Jul 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript
01:33pm, Tuesday, 29'th Jul 2025
Incyte Corporation (NASDAQ:INCY ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Christiana Stamoulis - Executive VP & CFO Greg Shertzer - Senior Director of Investor R
